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The business of genomic testing: a survey of early adopters
James M. Crawford, MD, PhD1, Lynn Bry, MD, PhD2, John Pfeifer, MD, PhD3,
Samuel K. Caughron, MD4, Stephen Black-Schaffer, MD5, Jeffrey A. Kant, MD, PhD6
and Jill H. Kaufman, PhD7
Purpose: The practice of “genomic” (or “personalized”) medicine
requires the availability of appropriate diagnostic testing. Our study
objective was to identify the reasons for health systems to bring
next-generation sequencing into their clinical laboratories and to
understand the process by which such decisions were made. Such
information may be of value to other health systems seeking to provide next-generation sequencing testing to their patient populations.

cost-effective. Barriers to implementation included implementation
cost; the time and effort needed to maintain this newer testing; challenges in interpreting genetic variants; establishing the bioinformatics infrastructure; and curating data from medical, ethical, and legal
standpoints. Ultimate success depended on alignment with institutional strengths and priorities and working closely with institutional
clinical programs.

Methods: A standardized open-ended interview was conducted
with the laboratory medical directors and/or department of pathology chairs of 13 different academic institutions in 10 different states.

Conclusion: These early adopters uniformly viewed genomic analysis as an imperative for developing their expertise in the implementation and practice of genomic medicine.

Results: Genomic testing for cancer dominated the institutional
decision making, with three primary reasons: more effective delivery
of cancer care, the perceived need for institutional leadership in the
field of genomics, and the premise that genomics will eventually be

introduction
Interest in the integration of “genomic medicine” into routine
medical care is rapidly increasing, given the association of
genetic variation with disease risk, development and progression of somatic diseases and of cancer, and drug efficacy or risk of
adverse events.1 The core technology is termed “next-generation
sequencing” (NGS), broadly defined as gene sequencing using
massively parallel strategies. The first publication on the use of
this technology was in 2005,2 in which sequencing of 25 million
bases at 99% or better accuracy in one 4-hour run was able to
achieve an approximately 100-fold increase in throughput over
existing Sanger sequencing technology. Nine years later, NGS
has found applications in sequencing the genome, exome, transcriptome, and microbiome, with more than 6,000 citations in
PubMed using this technology and >100 publications accruing
per month.3
Initial citations consisted of single reports of NGS being
applied to diagnose conditions for which conventional molecular methods had failed4 or for which known diseases (usually
cancer) were resistant to established pharmacologic therapies.5 Broader case-based experience is now forthcoming that
supports the concept that genomic testing can benefit patients
with undiagnosed disorders whose management has exhausted
all standard care options.6 Nevertheless, expansion of NGS
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utilization for more routine use still requires establishment of
an evidence base for most clinical applications.7,8 Achieving this
goal will require access to extensive information about patient
genotype, clinical phenotype, treatment outcomes, and the economics of delivering health care informed by genomic information.9 Regardless, having “genomic medicine” available now
is increasingly becoming a mark of leading health systems,10
based on the premise that efficiency of health-care delivery and
quality of life will be improved for their patients.11,12
The decision to bring NGS and genomic medicine into the
clinical armamentarium is challenging because the actual clinical evidence base for systematic use of this technology is not
firmly established. Such decision making is made more difficult by substantial uncertainty in how use and interpretation of
this technology will be paid for, both by federal programs and
by private payers.13 Obtaining regulatory approval for clinical
application of this technology, as through Clinical Laboratory
Improvement Amendments certification, is also a barrier that
to date only a few laboratories have cleared.
The Personalized Health Care Committee of the College of
American Pathologists is tasked with examining the role of
new technologies for molecular diagnostics and advising the
College on policies and programs to support the implementation of such technologies. A seven-person workgroup was
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commissioned to examine the business arguments for clinical
use of NGS. Given the lack of published information regarding
institutional implementation of NGS, the workgroup endeavored to identify the reasons for health systems choosing to
bring NGS into their clinical laboratories and to understand the
process by which such decisions were made. Interviews of the
laboratory directors for institutional “early adopters” of NGS
technologies were conducted. The interviews covered reasons
for establishing NGS testing within a health system (as opposed
to using a reference laboratory), the process for making such
a decision, barriers to bringing such testing in-house, lessons
learned, and key drivers of success. This study is complementary to a recently published study that examined challenges
and barriers in instituting genomic medicine from the perspective of institutional clinical leadership.14 Taken together, these
studies provide valuable information for current and future
institutional leaders, laboratory and clinical alike, considering
establishment of genomic testing programs.

MAtEriALS And METHODS
Selection of participants

“Early adopter” health systems were identified by the following
criteria: (i) having members serving on the College of American
Pathologists “Personalized Health Care Committee”; (ii) performing NGS testing for human diagnostics under a Clinical Laboratory
Improvement Amendments license; (iii) a record of peer-review
publication documenting the use of massively parallel sequencing
for human laboratory diagnostics; and/or (iv) institutional public
announcements of NGS implementation. We excluded for-profit
laboratories or independent laboratory networks based on the
premise that there was an inherent business argument for their
performing NGS testing as reference laboratories. Rather, health
systems were considered to constitute the “end users” of genomic
information and, in choosing to perform NGS testing themselves,
faced the more complex d
 ecision-making process. By these inclusion criteria, interviews of pathologist leaders from 13 academic
medical centers were conducted. All prospects accepted the invitation to be interviewed.

or individual. The word count for each institutional response
was used as an initial measure of the information content,15,16
with results presented in Table 1. Data were then analyzed
according to qualitative content analysis.17,18 This methodology
is appropriate for qualitative studies using open-ended interviews because it enables identification and quantification of
specific concepts mentioned by respondents.19–21

RESULTS
Survey metrics

Thirteen institutions fulfilled one or more of the inclusion criteria; these were located in 10 different states and one Canadian
province. Two of the US institutions had Clinical Laboratory
Improvement Amendments certification for clinical use of
NGS technologies. Table 1 shows the rank order of word count
for the 10 interview questions. There was no statistical difference in word count (data not shown) in relation to whether the
individual being interviewed was the medical director of the
molecular diagnostics laboratory (six interviews) or a pathology department chair (five interviews) or if the department
chair was invited to join the medical director in the interview
(two interviews).
The greatest information content pertained to p
 rospective
department and institutional decision making (question 1);
only limited information was given about strategies for measuring outcomes (question 9). This relative lack of content in
response to the latter is telling because institutions had to make
their decisions about implementing NGS in the absence of a priori evidence about whether doing so would help them achieve
improved metrics for more efficient health care and/or better
Table 1 Rank order of answers by word count
Question
1. Why did your institution decide to
adopt NGS?a

Survey instrument

A 1-hour telephone interview was designed, using open-ended
questions to give the interviewees an opportunity for discussion. Approximately 1 week before the interview, a standardized
list of 10 questions was sent to the interviewee. All interviews
were conducted by one interviewer (J.H.K.) and were recorded.
The 10 core questions were covered in the interview; for the
purposes of elaboration, the core questions were supplemented
by subquestions during the interview (the full set of questions
and subquestions is given in Supplementary Table S1 online).
This adaptive process allowed us to gain deeper insights into
our core question areas.
The complete interview transcripts were redacted to remove
information that could potentially identify a given institution
Genetics in medicine | Volume 16 | Number 12 | December 2014

1,318 ± 598 (533–2,162)

2. How did you implement NGS?

705 ± 337 (340–1,538)

6. What are your plans for engaging
payers in reimbursement for NGS?

455 ± 242 (75–710)

8. What lessons learned can you share
with future adopters of NGS?

294 ± 238 (120–1,038)

10. What can the College of American
Pathologists do to assist NGS
adopters?

294 ± 180 (1–639)

7. Are NGS services considered a
competitive advantage?

266 ± 169 (43–672)

4. How did you decide between
in-house versus send-out NGS
testing?

195 ± 180 (62–607)

5. How did you obtain funding for NGS?

110 ± 97 (6–307)

9. How will you measure successful
outcomes of adopting NGS?

103 ± 69 (6–228)

3. What clinical applications did you
choose for NGS?

Data compilation and analysis

Word count: mean ± SD
(range)

Total word count per institution

79 ± 108 (18–413)
3,802 ± 1,528 (2,076–6,421)

NGS, next-generation sequencing.
College of American Pathologists.

a
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patient outcomes. That being said, respondents spoke about (i)
the ability to identify druggable targets in cancer; (ii) elimination of redundant testing; (iii) earlier diagnosis; (iv) growth in
laboratory test volumes and expansion of testing menus; (v)
achieving “better educated” clinicians and pathologists; (vi)
increased interactions between the clinical laboratory and
treating clinicians; (vii) assessment of provider satisfaction with
laboratory support of patient care; and (viii) achievement of a
self-sustaining financial model.
Clinical applications and intended time line for
deployment

Ten institutions indicated cancer genomics to be the primary
clinical application for NGS testing. For the remaining three
institutions, medical genetics was the primary application.
Four institutions currently offered NGS testing clinically, seven
institutions were looking to deploy NGS testing within the next
6 to 12 months, for one institution the time line for deployment was uncertain, and one institution used send-out testing
to offer genomic testing. Regardless of the initial intent, five of
the seven institutions that gave estimates of relative target case
volumes assumed that they would be performing NGS testing
for both cancer genomics and medical genetics. The remaining
two assumed that 100% of their NGS testing would be for cancer genomics. One institution also planned on branching out
into NGS testing for infectious disease diagnostics.
Table 2 Reasons for deciding to offer in-house genomic
testing in the clinical practice setting
Reason

Number of
institutions

Demand from clinical colleagues

13

Anticipated efficiency of NGS testing over conventional
methods

12

Desire to gain institutional expertise in the technologies
and in informatics

9

Desire to advance the clinical application of “personalized
medicine”

7

Perceived requisite for institutional and departmental
stature

5

Value for research

5

Improved turnaround time for molecular diagnostics

4

Desire to develop expertise before NGS becomes a
commodity

3

Desire to have NGS expertise in-house for training and
research

3

Retention of institutional control over cost, turnaround
time, and validation

3

Desire for pathologists to provide leadership in clinical
care

2

Competitive market advantage

2

Belief that overall cost of clinical care would be reduced

2

Difficulty of coordinating outsourced and in-house test
results

1

Loss of research potential when outsourced

1

Recruitment of oncologists and cancer researchers

1

NGS, next-generation sequencing.
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Drivers for implementation

Table 2 shows the reasons given for deciding to perform clinical genomic testing, which are listed in order of decreasing
frequency of mention. Institutions frequently gave multiple reasons. Clinical demand and anticipated testing efficiency were
almost uniform reasons. A critical indicator was genomic testing that was already being “sent out” to a reference laboratory,
which could be redirected to an in-house facility if established.
This argument was even more compelling as the number of different tests being ordered increased, constituting the reason for
performing one larger gene panel in-house. Because the testing
platform is not gene or disease specific, testing could be consolidated. For only one institution was recruitment of oncologists (“cancer folks”) mentioned as a reason for deploying NGS
sequencing. None of the respondents mentioned retention of
personnel as a reason for bringing NGS testing in-house.
The institutional decision-making process

In 10 of the 13 institutions, officers above the level of department chair were involved in review and approval of the decision
to implement NGS testing, up to the level of the university president (one institution) and chief operating officer of the hospital
(five institutions). In two institutions, the dean of the college
of medicine was a key decision maker, and in one institution,
the cancer center director. In only three institutions the chair of
the department of pathology was the senior institutional officer
making the decision.
Institutional funding

Twelve institutions commented on the sources of funding for
bringing NGS in-house. For five institutions, 100% of the funding was from the hospital. For five other institutions, funding
was entirely from the department of pathology, either entirely
as research funds (one department) or as a mixture of research
and department funds (four departments). It was for three of
these latter five institutions that the decision-making process
had been entirely controlled by the pathology department chair.
In one institution, the department, hospital, and cancer center
contributed equally to the implementation of NGS testing; this
was the institution that involved the cancer center director in
the decision-making process. Finally, one Canadian institution
noted that funding for their NGS initiative was, ultimately, governmental because the Canadian government supports both
research and the clinical delivery system.
Interactions with payers

For the four institutions already offering NGS testing, each had
established mechanisms to work with payers for reimbursement; one institution also relied heavily on reimbursement
through “institutional accounts” in which the client institutions
paid the NGS testing laboratory through reference laboratory
agreements. These four respondents noted that agreements
between their institution and specific payers or client institutions were specific to their local environment and that these
might not be applicable to other institutions.
Volume 16 | Number 12 | December 2014 | Genetics in medicine
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Potential competitive value

Institutional expectations

Twelve of the 13 institutions were firm in their conviction that
the availability of NGS testing constituted a competitive market
advantage, both for their institutions as a whole and for their
cancer centers. For four institutions, expansion of geographic
reach of their health system constituted an additional perceived
value. As one respondent stated, NGS testing was viewed as
having a “halo effect” on the overall stature of the institution
and its cancer center. The last institution considered that the
clinical utility of NGS testing was not sufficiently established, so
that the competitive value was as yet uncertain.
The question can be asked of whether competitive market
advantage is an appropriate justification for implementing NGS
testing. A starting point for this issue is performance of NGS
testing in-house. “The whole reason for doing this is to be able
to provide the same or often better service than the single gene
test, at substantially lower costs.” Further, “In our practice environment, the standard of care for certain malignancies [can be
met] faster and cheaper by NGS, than by doing those panels of
genes by Sanger sequencing.” “It is not about the sequencing
machine. It is about the cost-per-test.” Beyond that, and even
drawing on only case-based experience, “avoidance of futile
therapeutic regimes is a powerful argument for the use of NGS
testing.” This translates into oncologists “no longer planning
treatments based on one particular gene test, but on a number
of different genetic abnormalities.”

Only four respondents commented on institutional expectations for outcomes as factoring into the decision-making
process. These were enrolling patients in clinical trials (two
institutions) and obtaining grant funding (one institution). The
fourth institution did not expect financial sustainability for at
least 5 years.

Table 3 Barriers to deployment of genomic testing and
unanticipated needs
Issue

Number of
institutions

Barriers
Scarcity of informatics expertise

7

Rapidly changing nature of technologies

4

Validation of clinical testing protocols

3

Expense of implementation

3

Amount of data to curate

2

Difficulty of getting first application deployed

2

E thics of reporting “all data” as opposed to “clinically
indicated data”

2

L ack of institutional resourcing of staff on-the-job
training

2

Uncertainty of reimbursement

1

Uncertainty of clinical utility

Barriers to implementation

Although only one survey question asked about “lessons
learned” (question 8), sprinkled throughout the interview
transcripts were comments about encountering and overcoming barriers to NGS implementation and encountering unanticipated needs (Table 3). A recurrent theme in the interviews
was the challenge of having adequate institutional expertise in
informatics. The two institutions with large existing research
programs in genomics obtained valuable mentorship in starting
up the bioinformatics for clinical genomics. Two other institutions were successful in recruiting experts in both genomic
testing and informatics. Such recruitment was acknowledged
as a significant barrier to overcome because “these people are
in demand, and they will have competing job offers.” These two
institutions spoke in glowing terms about the positive effect of
these experts on the institution. By contrast, two other institutions noted that they obtained institutional funding for equipment acquisition but not the resources for recruitment, staff
training, or equipment validation in order to get NGS operational. Not surprisingly, these two institutions were not yet
operational for their NGS testing.
Lessons learned

Each institution offered its own lessons learned, with substantive overlap among institutions (Table 4). Common themes
were that implementation took or was taking longer, and
Table 4 Lessons learned from implementing NGS testing
Lesson learned

Number of
institutions

Deployment was more complicated than anticipated (and
took longer)

4

Need a more complete multidisciplinary team

4

Need to start with known testing applications before
building further

4

1

Need to understand the market and anticipated clinical
testing load

2

8

Need to play to institutional strengths in clinical
programming

2

 eed for additional on-the-job training for
N
technologists

Need to verify adequacy of bioinformatics (analytics)

2

Need for training of pathologists and clinical scientists

5

2

Need to develop staff and professional expertise

5

Need to be adequately capitalized and not build
piecemeal

 eed for a full-time next-generation sequencing
N
project manager

2

Need to have a local research laboratory as a partner

1
1

Need for additional institutional IT resources

1

Need to have a multidisciplinary stakeholder advisory
group

 eed for a multidisciplinary institutional governance
N
committee

1

Need to specify patient selection for performance of NGS
testing

1

Unanticipated needs

IT, information technology.
Genetics in medicine | Volume 16 | Number 12 | December 2014
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required more thorough involvement of clinical stakeholders,
than anticipated. Four institutions started with a commercially
established testing application before expanding into a broader
test menu. Ironically, even for cancer-oriented institutions,
germ-line testing for medical genetics was a plausible initial
application for NGS so as to gain initial expertise and validate
testing platforms. A related recommendation was to make sure
that the chosen NGS testing aligned well with institutional
strengths in clinical expertise, research programming, and, if
available, informatics. This would help ensure that clinical case
volumes would justify the performance of relevant NGS testing
in-house. A second institution reported on the need to have a
multidisciplinary advisory group to establish clear guidelines
for which patients should be offered NGS testing as a lesson
learned.
In the respondents’ words, these are additional thoughts
about achieving success:
•

•

•

•
•
•

•
•
•

“If you are a small place, wait for (i) the platforms, informatics, and reporting to be worked out, and (ii) for
research to demonstrate that [NGS] is clinically useful
and superior. [From an implementation standpoint], you
are better off if you can wait until NGS is pre-packaged,
but then you will not be a leader in the field.”
“If you are going to be a leader, the greatest barrier is optimizing the design of the gene panel for the clinical application. These panels must be tested and validated before
clinical implementation.”
“It is a lot easier to generate the data than [to] interpret it.
You have to adequately resource the informatics function
for interpretation. If you don’t, you end up with a very
expensive paper weight in your department.”
“It is important to be adequately capitalized when you
start. Trying to build NGS in a piecemeal fashion is not a
successful strategy.”
“You must do high quality DNA extractions.”
“You have to work closely with clinical colleagues, so as to
avoid offering something that will not be useful to their
clinical practice. Match your platform with the testing
that is needed.”
“Start small. Build your volume gradually so that you
keep your quality up.”
“Understand the limitations of the technology. For testing
specific small regions of the genome, NGS may not be the
preferred technology.”
“Decide what data will be reported. Will you report information that is not being tested for?”

Measurement of outcomes

Intended evaluation of the outcomes of instituting NGS testing
was qualitative in nature, along the lines of better management
of patients (five institutions) and earlier clinical diagnosis (two
institutions). When mentioned, intended quantitative measures included growth in test volumes, expansion in test menus,
958
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and elimination of other laboratory testing (four, two, and one
institutions, respectively). Surveys were planned to assess physician and/or patient satisfaction (one institution each). In two
institutions, achievement of a financially sustainable model was
viewed as a key outcome measure.
Assistance from organized pathology

The respondents gave strong suggestions for contributions
that could be made by the College of American Pathologists.
Education of the professional and technical workforce for
the performance of NGS testing was most frequently mentioned (seven institutions), followed by core activities of the
College’s Laboratory Accreditation Program (testing standards, validation protocols, checklists, and proficiency testing).
Dissemination of information about coding, billing, and reimbursement, as well as about national data networks and databases was mentioned by more than one institution.
Strategies for implementation

Three general strategies emerged for the implementation of
NGS testing in-house: (i) overlaying NGS testing on established
institutional polymerase chain reaction–based testing, before
expanding the test menu; (ii) beginning with commercially
validated NGS testing platforms, before expanding the test
menu; (iii) starting with customized (but limited) NGS panels
for specific applications, before expanding the test menu. An
alternative to these is making the decision ab initio to outsource NGS testing. In this last instance, a derivative decision
is then whether to have the genomic analysis also performed on
an outsourced basis or to perform the informatics analysis inhouse. The relevant value of each starting point is determined
by local institutional needs and priorities. In turn, the timing
and scope of expansion in available NGS test menus and applications will be determined in part by the success of the initial
implementation and by the continued evolution of institutional
strategies and priorities.
Proposed flowchart for institutional decision making and
implementation

These survey responses permit the construction of a proposed
flowchart for the institutional process of bringing NGS testing
in-house (Figure 1). Although each institution will have its
own unique requirements, this flowchart attempts to capture
the essential elements for institutional decision making and
project management.

DISCUSSION
The institutional decision to implement massively parallel
sequencing, as exemplified by NGS, presents both an opportunity and a challenge. Because NGS testing is performed by
a clinical laboratory, we surveyed the laboratory leaders, who
carry ultimate responsibility for the validity of such testing.
Whether medical director of a molecular diagnostic laboratory
or department chair, these individuals are pathologists: physicians who are experts in the performance, interpretation, and
Volume 16 | Number 12 | December 2014 | Genetics in medicine
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Identify clinical need
Examine institutional strengths
Research programs

Clinical programming

Informatics

Examine institutional priorities
Clinical programming

Research and education

Market and stature

Establish business plan
Reimbursement strategies

Institutional resourcing

Research resources

Prioritize initial clinical applications

Unanticipated
resources

Develop project plan
Timeline and monitors

Governance

Outcome measures

Obtain institutional approval
Implement
Monitor

Figure 1 Schematic for institutional decision making and project strategy.

clinical application of laboratory diagnostics. For these respondents, institutional demand and the challenges of implementation were the primary issues to be faced.
As a dominant initiating theme, demand for NGS testing
from clinical colleagues most often originated with oncologists. An equally dominant theme was the expectation that
massively parallel NGS testing would, ultimately, be more efficient than single test–based methodologies. That being said, a
critical early decision was whether to implement custom panels
or to implement commercially available testing products. The
former permits tailoring of the panels to specific institutional
needs; the latter enables implementation of testing that already
has been validated elsewhere. Recommendations were made in
favor of each starting strategy.
Returning to the question of whether “competitive advantage” or “recognition” is a justifiable reason for implementing NGS, there are a number of convergent considerations.
Synthesizing their many responses, the institutions choosing
to implement NGS sequencing (i) wished to attract patients to
their institution; (ii) have both outstanding clinicians and laboratorians for the practice of genomic medicine; (iii) contribute
to new knowledge about the efficacy of NGS testing in patient
care; and (iv) control costs, testing algorithms, and the quality
of NGS testing. In the eyes of these institutions, acknowledging
that “recognition” and “competitive advantage” might also be
forthcoming is not so much justification as important collateral
for being an institution that advances innovation in health care.
The reported barriers and challenges in implementing NGS testing begin with having insufficient institutional
expertise in informatics and in the technical performance of
Genetics in medicine | Volume 16 | Number 12 | December 2014

testing. Additional issues included the need for test validation, competent performance and interpretation of the testing, determination of test utility, and financing, both of the
initial implementation and of the ongoing testing program.
Collectively, these issues reflect the unique requirements
imposed by the regulatory environment for performing clinical testing22 as opposed to testing that is done for research purposes.23 These barriers and challenges are distinctly different
from the institutional challenges reported by Manolio et al.,14
which were limited evidence or consensus for which genomic
variants were medically relevant; lack of reimbursement for
genomically driven clinical interventions (which is different
from concern about reimbursement for the performance of the
genomic testing); and burden to patients and clinicians not only
in assaying and reporting of testing but also in intervening and
following up on genomic findings.
There was commonality in one challenge found by us and
reported by Manolio et al.,14 which for our study respondents
was the amount of data that needed to be curated and for
respondents in the Manolio study was the need for a framework to define and catalog clinically actionable genomic variants. Key for establishing such a framework is a knowledge
base that captures sequence variants and their phenotypic associations.14,24 It is therefore notable that a separate workgroup of
the College of American Pathologists Personalized Healthcare
Committee is currently examining the principles and specifications for “clinically actionable” genomic databases, and the
actual creation and curation of such databases is a pan-industry
effort. That being said, the presence of such databases is only
an intermediate step. Professional interpretation of genomic
959
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variants found during testing on individual patients must occur,
and it is this step that constitutes the practice of medicine. The
finalization of a test report requires both access to appropriate
genomic databases and judgment of the clinical importance of
test findings for the individual patient.
Regarding reimbursement for NGS testing, the four laboratories already performing NGS testing had established reportedly
productive conversations with payers, and six other laboratories
in the process of implementation were optimistic about communication with payers. One institution had well-established
payment mechanisms through interinstitutional agreements.
With that one exception, institutions were not expecting financial sustainability of their NGS testing in the near future, and
consumption of institutional resources, including research
funds, was a necessary requirement for ongoing performance
of such testing. This simple fact underscores the difficulty facing institutions in deciding whether or not to implement NGS
testing.
This report highlights the challenges of instituting NGS
testing, in the form of the need for additional institutional
resources, and the diversity of unexpected issues. A theme that
overlaps with the Manolio study is the highly multidisciplinary
nature of implementing genomic testing.14 A corollary is identified in this study: the NGS testing chosen should align with
institutional strengths both in clinical programming and in
research initiatives. We note that, in more than 38,000 words
of interview content, the word “governance” was mentioned
only twice, once as an unanticipated additional requirement for
implementation and once as a lesson learned after implementation. We have incorporated the requirement for governance
as a requirement ab initio for implementing genomic medicine
(Figure 1). We also recommend that the patient voice be represented in such a governance mechanism because genomic
medicine not only cuts across technical practice and medical
management but also invokes ethical and societal issues.6,25
The limited information content for assessment of outcomes
was striking. Establishment of quantitative metrics is immediately possible for test volume, test menu, and financial sustainability, and it is achievable for physician satisfaction and
patient satisfaction through survey mechanisms. However, the
actual assessment of health-care outcomes remains elusive.
The relative paucity of institutional specifications for assessing
outcomes challenges the establishment of an evidence base for
the presumed clinical utility of genomic medicine. We consider
setting up the metrics prospectively for quantitative assessment
of patient and population outcomes essential for institutional
deployments of NGS technologies. Reporting on such metrics,
including whether implementation of NGS creates new problems in delivering effective patient care, should remain a priority for future studies.
This study was not designed to determine whether the decision to implement NGS testing was actually sound. Second, for
these “early adopters,” metrics for outcomes were not yet available. Rather, in our interviewing this first wave of NGS adopters, their real-time experiences can instead serve as a guide for
960
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other institutions or health-care entities giving consideration to
the value of incorporating genomic medicine into their clinical
programming, in advance of an extensive evidence base being
established for the ultimate utility of genomic medicine. By
also creating an extensive lexicon of key concepts, this study
helps advance a recommendation by Manolio et al.14 that institutional efforts to establish genomic medicine programs should
benefit from collaboration using a more structured sharing of
best practices. In doing so, this study helps delineate the key
elements of decision making and implementation, and it can
serve as a guide for future institutions and health systems
that are considering offering genomic testing to their patient
populations.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper
at http://www.nature.com/gim
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